Key result
Patients with biopsy-proven NAFLD had significantly higher pulse wave velocity (7.2 vs 6.2 m/s, P<0.001) and augmentation index (21.3% vs 17.2%, P=0.01) compared to controls.
Why the study?
It remained open whether an association exists between the extent of vascular and liver stiffness in patients with biopsy-proven NAFLD.
Is arterial stiffness associated with liver stiffness and fibrosis severity in patients with biopsy-proven NAFLD?
Case-Control (n=180)
Is arterial stiffness associated with liver stiffness and fibrosis severity in patients with biopsy-proven NAFLD?
Absolute Event Rate: 7.2% vs 6.2%
p-value: p=<0.001
Arterial stiffness increases in parallel with liver stiffness in patients with biopsy-proven NAFLD, highlighting the need for cardiovascular risk assessment in those with advanced liver fibrosis.
Arterial stiffness was associated with liver stiffness in biopsy-proven NAFLD; leaves open whether fibrosis severity informs cardiovascular risk stratification.
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) has been associated with an increased arterial stiffness. However, the question as to whether an association exists between the extent of vascular and liver stiffness in patients with biopsy-proven NAFLD remains open. In this study, we sought to investigate whether pulse wave velocity (PWV) and augmentation index (AIx) - two common indices of arterial stiffness - are associated with (a) liver stiffness measurement (LSM) on transient elastography (TE) and (b) histological liver fibrosis. PATIENTS AND METHODS: We examined 125 patients with biopsy-proven NAFLD and 55 age-matched and sex-matched controls. Arterial stiffness of the brachial artery was measured using a Mobil-O-Graph arteriography system. LSM was assessed using TE, whereas the presence of advanced fibrosis (F ≥ 3) was determined on histology. RESULTS: Patients with NAFLD had higher PWV [median: 7.2 (6.3-8.2) and 6.2 (5.5-6.7) m/s, respectively, P < 0.001] and AIx (mean: 21.3 ± 13.5 and 17.2 ± 11.9%, respectively, P=0.01) compared with the controls. LSM showed positive correlations with both PWV (ρ = 0.300; P<0.01) and AIx (ρ = 0.223, P = 0.02). Both indices of arterial stiffness were higher in patients with advanced fibrosis than in those with nonadvanced fibrosis (F ≤ 2). CONCLUSION: The severity of arterial and liver stiffness increases in parallel in patients with biopsy-proven NAFLD. Systematic risk assessment for reducing arterial stiffness is recommended in the presence of TE-determined advanced fibrosis.
No takes yet. Share an insight, caveat, or question.
Bilgin et al. (2019) conducted a case-control in Nonalcoholic fatty liver disease (NAFLD) (n=180). Biopsy-proven NAFLD vs. Age-matched and sex-matched controls was evaluated on Pulse wave velocity (PWV) (p=<0.001). Patients with biopsy-proven NAFLD had significantly higher pulse wave velocity (7.2 vs 6.2 m/s, P<0.001) and augmentation index (21.3% vs 17.2%, P=0.01) compared to controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: